

# Alberto Ocana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2906455/publications.pdf>

Version: 2024-02-01

236  
papers

11,910  
citations

44042

48  
h-index

31818

101  
g-index

239  
all docs

239  
docs citations

239  
times ranked

18699  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110726.	1.4	7
2	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2022, , 1.	1.6	2
3	Abstract P2-01-18: Orthogonal assessment of <i>PIK3CA</i> and <i>ESR1</i> mutation detection in longitudinal cfDNA samples from endocrine-resistant HR+/HER2- advanced breast cancer patients using dPCR and NGS-based SafeSEQ technology. <i>Cancer Research</i> , 2022, 82, P2-01-18-P2-01-18.	0.4	0
4	Abstract P3-05-06: Genome-wide DNA methylation analysis identifies novel biomarkers associated with risk of relapse beyond oncotype DX recurrence-score risk assessment within HR+/HER2- early-stage breast cancer patients. <i>Cancer Research</i> , 2022, 82, P3-05-06-P3-05-06.	0.4	0
5	Clinical considerations for the design of PROTACs in cancer. <i>Molecular Cancer</i> , 2022, 21, 67.	7.9	37
6	Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 106.	3.5	6
7	Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. <i>Cancers</i> , 2022, 14, 154.	1.7	30
8	Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5476.	1.8	2
9	Multifunctional PLA/Gelatin Bionanocomposites for Tailored Drug Delivery Systems. <i>Pharmaceutics</i> , 2022, 14, 1138.	2.0	7
10	Clinical benefit of cancer drugs approved in Switzerland 2010–2019. <i>PLoS ONE</i> , 2022, 17, e0268545.	1.1	2
11	Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial. <i>Clinical and Translational Oncology</i> , 2021, 23, 764-772.	1.2	13
12	In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 569-580.	2.1	16
13	Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer. <i>Cancers</i> , 2021, 13, 833.	1.7	11
14	MZ1 co-operates with trastuzumab in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 106.	3.5	7
15	Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3836.	1.8	2
16	Genomic Correlates of DNA Damage in Breast Cancer Subtypes. <i>Cancers</i> , 2021, 13, 2117.	1.7	3
17	Serological Tests in the Detection of SARS-CoV-2 Antibodies. <i>Diagnostics</i> , 2021, 11, 678.	1.3	9
18	Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade. <i>Scientific Reports</i> , 2021, 11, 10843.	1.6	1

#	ARTICLE	IF	CITATIONS
19	HGK promotes metastatic dissemination in prostate cancer. <i>Scientific Reports</i> , 2021, 11, 12287.	1.6	8
20	Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment. <i>Cancers</i> , 2021, 13, 3387.	1.7	24
21	Altered proTGF $\beta$ <sub>1</sub> /cleaved TGF $\beta$ <sub>1</sub> ratios offer new therapeutic strategies in renal carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 256.	3.5	1
22	Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer. <i>Cancers</i> , 2021, 13, 4118.	1.7	7
23	Generation of Antibody-Drug Conjugate Resistant Models. <i>Cancers</i> , 2021, 13, 4631.	1.7	6
24	Mithramycin delivery systems to develop effective therapies in sarcomas. <i>Journal of Nanobiotechnology</i> , 2021, 19, 267.	4.2	11
25	Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer. <i>Pharmaceutics</i> , 2021, 13, 1559.	2.0	3
26	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 313.	3.5	6
27	P70.07 Examples of Population Kinetics (PopKin) Assessments of Progression-Free (PFS) and Overall Survival (OS). <i>Journal of Thoracic Oncology</i> , 2021, 16, S1213.	0.5	0
28	The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer. <i>Cancers</i> , 2021, 13, 5307.	1.7	7
29	Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates. <i>Frontiers in Immunology</i> , 2021, 12, 786069.	2.2	7
30	Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 805336.	1.8	7
31	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 827625.	1.3	7
32	Medical Oncology Workload in Europe: One Continent, Several Worlds. <i>Clinical Oncology</i> , 2020, 32, e19-e26.	0.6	15
33	Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms. <i>Cancer Letters</i> , 2020, 470, 161-169.	3.2	11
34	Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer. <i>Pharmaceutics</i> , 2020, 12, 986.	2.0	41
35	10P Genomic profiles of CD47 in breast tumours predict outcome and are associated with immune activation and enrichment of pro-tumoral macrophage markers. <i>Annals of Oncology</i> , 2020, 31, S1420.	0.6	0
36	Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9034.	1.8	5

#	ARTICLE	IF	CITATIONS
37	Breast Cancer Heterogeneity and Response to Novel Therapeutics. <i>Cancers</i> , 2020, 12, 3271.	1.7	40
38	Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer. <i>Cancer Letters</i> , 2020, 491, 50-59.	3.2	13
39	Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. <i>Cancers</i> , 2020, 12, 2223.	1.7	18
40	Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia. <i>Breast</i> , 2020, 54, 160-163.	0.9	12
41	Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine. <i>Frontiers in Oncology</i> , 2020, 10, 605633.	1.3	25
42	Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial. <i>Scientific Reports</i> , 2020, 10, 16634.	1.6	12
43	An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy. <i>Pharmaceutics</i> , 2020, 12, 802.	2.0	62
44	Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. <i>Cancer Medicine</i> , 2020, 9, 7888-7895.	1.3	5
45	91P Transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer. <i>Annals of Oncology</i> , 2020, 31, S277-S278.	0.6	0
46	Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6018.	1.8	52
47	Proteolysis targeting chimeras (PROTACs) in cancer therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 189.	3.5	36
48	Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1. <i>Cancers</i> , 2020, 12, 2243.	1.7	22
49	Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 431-444.	2.1	11
50	Potential insights from population kinetic assessment of progression-free survival curves. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103039.	2.0	3
51	Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 3117-3127.	1.6	12
52	Integrin $\alpha 6$ Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 143-151.	1.6	6
53	Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. <i>Trends in Cancer</i> , 2020, 6, 130-146.	3.8	58
54	HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. <i>EMBO Molecular Medicine</i> , 2020, 12, e11498.	3.3	30

#	ARTICLE	IF	CITATIONS
55	HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. <i>Breast Cancer Research</i> , 2020, 22, 15.	2.2	53
56	Monitoring of PIK3CA and ESR1 mutations in circulating tumor DNA as predictive and prognostic biomarkers in patients with endocrine-resistant ER+/HER2- advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13045-e13045.	0.8	0
57	Genomic mapping to identify mutations in RYR2 and AHNAK in basal-like breast tumors expressing PD-L1.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1027-1027.	0.8	0
58	Associations between safety and tolerability and reporting of health-related quality of life in phase III randomized trials in common solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19206-e19206.	0.8	0
59	Screening and Preliminary Biochemical and Biological Studies of [RuCl( <i>p</i> -cymene)(N,N-bis(diphenylphosphino)-isopropylamine)] <sub>4</sub> in Breast Cancer Models. <i>ACS Omega</i> , 2019, 4, 13005-13014.	1.6	7
60	Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. <i>Oncolmmunology</i> , 2019, 8, e1629780.	2.1	34
61	Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT). <i>Annals of Oncology</i> , 2019, 30, v91-v92.	0.6	0
62	Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer. <i>Scientific Reports</i> , 2019, 9, 14934.	1.6	19
63	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1040.	1.3	38
64	In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer. <i>Annals of Oncology</i> , 2019, 30, v99.	0.6	0
65	Poly(Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy. <i>Nanomaterials</i> , 2019, 9, 1208.	1.9	24
66	Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 383.	3.5	62
67	The tyrosine kinase inhibitor dasatinib blocks tumour growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer. <i>Annals of Oncology</i> , 2019, 30, v10.	0.6	0
68	Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 77, 11-19.	3.4	14
69	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. <i>PLoS ONE</i> , 2019, 14, e0209134.	1.1	16
70	TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells. <i>Cancer Letters</i> , 2019, 453, 34-44.	3.2	12
71	Mapping Bromodomains in breast cancer and association with clinical outcome. <i>Scientific Reports</i> , 2019, 9, 5734.	1.6	11
72	Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population. <i>Cancers</i> , 2019, 11, 493.	1.7	15

#	ARTICLE	IF	CITATIONS
73	Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2019, 2, 448-455.	2.6	10
74	A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2802.	2.2	24
75	Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastatic Breast Cancer. <i>Nanomaterials</i> , 2019, 9, 1793.	1.9	40
76	Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 693-701.	1.1	34
77	Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. <i>Mayo Clinic Proceedings</i> , 2019, 94, 74-83.	1.4	10
78	Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual. <i>JAMA Oncology</i> , 2019, 5, 107.	3.4	2
79	Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1486.	1.3	20
80	Population kinetics of progression free survival (PFS).. <i>Journal of Clinical Oncology</i> , 2019, 37, e18251-e18251.	0.8	1
81	Functioning of autobiographical memory specificity and self-defining memories in people with cancer diagnosis. <i>PeerJ</i> , 2019, 7, e8126.	0.9	10
82	Resistance to Antibody-Drug Conjugates. <i>Cancer Research</i> , 2018, 78, 2159-2165.	0.4	136
83	Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. <i>Cancer Medicine</i> , 2018, 7, 1896-1907.	1.3	14
84	Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2018, 30, 215-224.	0.6	28
85	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2018, 110, 486-492.	3.0	70
86	Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 413-425.	1.1	14
87	Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 613-623.	1.1	36
88	Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. <i>European Journal of Cancer</i> , 2018, 94, 199-205.	1.3	21
89	Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 62, 1-8.	3.4	69
90	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 31-39.	3.0	129

#	ARTICLE	IF	CITATIONS
91	Reporting of Randomized Trials in Common Cancers in the Lay Media. <i>Oncology</i> , 2018, 94, 65-71.	0.9	1
92	Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1798-1804.	0.8	27
93	Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene. <i>PLoS ONE</i> , 2018, 13, e0207776.	1.1	11
94	Refining Early Antitumoral Drug Development. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 922-925.	4.0	17
95	Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 71, 68-75.	3.4	9
96	Transcriptome evolution from breast epithelial cells to basal-like tumors. <i>Oncotarget</i> , 2018, 9, 453-463.	0.8	11
97	Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results. <i>Oncotarget</i> , 2018, 9, 31915-31919.	0.8	14
98	Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 725-732.	1.1	9
99	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. <i>Clinical and Translational Oncology</i> , 2018, 20, 1548-1556.	1.2	10
100	Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer. <i>Oncotarget</i> , 2018, 9, 15061-15067.	0.8	2
101	Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 337-343.	1.6	4
102	Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. <i>Cancer Treatment Reviews</i> , 2017, 56, 1-7.	3.4	42
103	Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression. <i>Experimental and Molecular Pathology</i> , 2017, 102, 455-474.	0.9	17
104	Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications. <i>Molecular Oncology</i> , 2017, 11, 1788-1805.	2.1	7
105	Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2552-2562.	1.9	44
106	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 60, 53-59.	3.4	21
107	Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2017, 59, 46-53.	3.4	2
108	Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. <i>Scientific Reports</i> , 2017, 7, 17530.	1.6	53



#	ARTICLE	IF	CITATIONS
109	Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. <i>Cancer Research</i> , 2017, 77, 4639-4651.	0.4	103
110	Neutrophils in cancer: prognostic role and therapeutic strategies. <i>Molecular Cancer</i> , 2017, 16, 137.	7.9	295
111	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , 2017, 8, 73144-73153.	0.8	24
112	Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. <i>PLoS ONE</i> , 2017, 12, e0175128.	1.1	28
113	DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer. <i>Oncotarget</i> , 2017, 8, 62834-62841.	0.8	13
114	Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 19478-19490.	0.8	23
115	Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. <i>Oncotarget</i> , 2017, 8, 22218-22234.	0.8	46
116	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. <i>Oncotarget</i> , 2017, 8, 21733-21740.	0.8	18
117	BET inhibitors as novel therapeutic agents in breast cancer. <i>Oncotarget</i> , 2017, 8, 71285-71291.	0.8	33
118	Relevance of randomised controlled trials in oncology. <i>Lancet Oncology</i> , The, 2016, 17, e560-e567.	5.1	74
119	Bias in reporting of randomised clinical trials in oncology. <i>European Journal of Cancer</i> , 2016, 61, 29-35.	1.3	42
120	Under-reporting of harm in clinical trials. <i>Lancet Oncology</i> , The, 2016, 17, e209-e219.	5.1	76
121	Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy. <i>Cancer Treatment Reviews</i> , 2016, 50, 168-174.	3.4	12
122	Honorary and ghost authorship in reports of randomised clinical trials in oncology. <i>European Journal of Cancer</i> , 2016, 66, 1-8.	1.3	23
123	Toward Value-Based Pricing to Boost Cancer Research and Innovation. <i>Cancer Research</i> , 2016, 76, 3127-3129.	0.4	15
124	<i>In Silico</i> Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1823-1833.	1.9	23
125	Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies. <i>Cancer Treatment Reviews</i> , 2016, 43, 67-73.	3.4	28
126	Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. <i>Clinical Oncology</i> , 2016, 28, 283-291.	0.6	3



#	ARTICLE	IF	CITATIONS
127	Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 1-8.	1.1	10
128	Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration. <i>JAMA Oncology</i> , 2016, 2, 744.	3.4	17
129	Circulating DNA and Survival in Solid Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 399-406.	1.1	30
130	Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node. <i>Oncogene</i> , 2016, 35, 2756-2765.	2.6	18
131	Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , 2016, 11, e0154789.	1.1	31
132	<i>In silico</i> analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. <i>Oncotarget</i> , 2016, 7, 22865-22872.	0.8	21
133	Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies. <i>Oncotarget</i> , 2016, 7, 45042-45051.	0.8	21
134	Targeting the EGF/HER Ligand-Receptor System in Cancer. <i>Current Pharmaceutical Design</i> , 2016, 22, 5887-5898.	0.9	51
135	Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development. <i>Current Cancer Drug Targets</i> , 2016, 17, 48-52.	0.8	2
136	Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel. <i>Radiology and Oncology</i> , 2015, 49, 402-408.	0.6	7
137	1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer. <i>European Journal of Cancer</i> , 2015, 51, S176-S177.	1.3	1
138	Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study. <i>PLoS ONE</i> , 2015, 10, e0122735.	1.1	14
139	Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0132449.	1.1	41
140	Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1298-1299.	0.8	32
141	Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 839-843.	1.0	6
142	Author Financial Conflicts of Interest, Industry Funding, and Clinical Practice Guidelines for Anticancer Drugs. <i>Journal of Clinical Oncology</i> , 2015, 33, 100-106.	0.8	47
143	Pathological complete response in breast cancer. <i>Lancet, The</i> , 2015, 385, 113.	6.3	1
144	One step forward, two steps back: The story of everolimus in advanced breast cancer. <i>Breast</i> , 2015, 24, 529-531.	0.9	4

#	ARTICLE	IF	CITATIONS
145	Influence of censoring on conclusions of trials for women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 721-724.	1.3	16
146	Failures in Phase III: Causes and Consequences. <i>Clinical Cancer Research</i> , 2015, 21, 4552-4560.	3.2	70
147	Response. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv244.	3.0	1
148	Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2015, 67, 740-749.	0.9	166
149	Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 27923-27937.	0.8	24
150	Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. <i>Oncotarget</i> , 2015, 6, 30057-30071.	0.8	15
151	Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. <i>Oncotarget</i> , 2015, 6, 31272-31283.	0.8	8
152	Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. <i>Oncotarget</i> , 2015, 6, 32856-32867.	0.8	17
153	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , 2015, 6, 39538-39549.	0.8	27
154	Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e95219.	1.1	140
155	Achilles' heel of triple negative cancer. <i>Oncoscience</i> , 2014, 1, 115-116.	0.9	2
156	Raising Concern About the American Society of Clinical Oncology Conflict of Interest Policy Amendment. <i>Journal of Clinical Oncology</i> , 2014, 32, 3197-3197.	0.8	2
157	Association of Aromatase Inhibitors With Coronary Heart Disease in Women With Early Breast Cancer. <i>Cancer Investigation</i> , 2014, 32, 99-104.	0.6	20
158	A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. <i>Investigational New Drugs</i> , 2014, 32, 1269-1277.	1.2	45
159	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 295-307.	2.7	5
160	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2014, 40, 1048-1055.	3.4	34
161	Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3634-3642.	0.8	64
162	Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt319-djt319.	3.0	279

#	ARTICLE	IF	CITATIONS
163	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer, 2014, 14, 302.	1.1	49
164	Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1204-1212.	1.1	519
165	Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2014, 146, 235-244.	1.1	73
166	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2014, 106, dju124.	3.0	2,202
167	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene, 2014, 33, 148-156.	2.6	78
168	Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis. PLoS ONE, 2014, 9, e88238.	1.1	51
169	Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget, 2014, 5, 11308-11318.	0.8	40
170	Achilles's™ heel of triple negative cancer. Oncoscience, 2014, 1, 763-764.	0.9	2
171	Achilles' heel of triple negative cancer. Oncoscience, 2014, 1, 763-4.	0.9	2
172	Fulvestrant for advanced breast cancer: A meta-analysis. Cancer Treatment Reviews, 2013, 39, 753-758.	3.4	29
173	Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?. Cancer and Metastasis Reviews, 2013, 32, 211-227.	2.7	119
174	The evolving landscape of protein kinases in breast cancer: Clinical implications. Cancer Treatment Reviews, 2013, 39, 68-76.	3.4	20
175	Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Annals of Oncology, 2013, 24, 1238-1244.	0.6	104
176	Multidimensional Challenges in Clinical Drug Development, Regulatory Approval, and Marketing. Journal of Clinical Oncology, 2013, 31, 1252-1253.	0.8	2
177	Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept. Clinical Cancer Research, 2013, 19, 4931-4940.	3.2	21
178	HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis. Journal of the National Cancer Institute, 2013, 105, 266-273.	3.0	168
179	Targeting HER Receptors in Cancer. Current Pharmaceutical Design, 2013, 19, 808-817.	0.9	39
180	Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. Annals of Oncology, 2012, 23, 2977-2982.	0.6	15

#	ARTICLE	IF	CITATIONS
181	Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1342-1352.	1.9	47
182	Benefits and Harms of Detecting Clinically Occult Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1542-1547.	3.0	13
183	How valid are claims for synergy in published clinical studies?. <i>Annals of Oncology</i> , 2012, 23, 2161-2166.	0.6	33
184	Management of small HER2 overexpressing tumours. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 289-293.	1.1	14
185	Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?. <i>European Journal of Cancer</i> , 2012, 48, 385-388.	1.3	84
186	Meta-Analysis of HER3 Expression and Prognosis in Solid Tumors. <i>Annals of Oncology</i> , 2012, 23, ix91.	0.6	1
187	The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs. <i>Journal of Clinical Oncology</i> , 2012, 30, 3012-3019.	0.8	152
188	Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 769-781.	1.1	165
189	Targeting HER Receptors in Cancer. <i>Current Pharmaceutical Design</i> , 2012, 19, 808-817.	0.9	3
190	Drug resistance in metastatic castration-resistant prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 12-23.	12.5	286
191	P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. <i>Oncogene</i> , 2011, 30, 1059-1071.	2.6	92
192	Clinical Research: Show Us the Data. <i>Journal of Clinical Oncology</i> , 2011, 29, 1099-1100.	0.8	9
193	Preclinical development of molecular-targeted agents for cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 200-209.	12.5	145
194	Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1299-1309.	3.0	538
195	When Are "Positive" Clinical Trials in Oncology Truly Positive?. <i>Journal of the National Cancer Institute</i> , 2011, 103, 16-20.	3.0	101
196	Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs. <i>Journal of Clinical Oncology</i> , 2011, 29, 2543-2549.	0.8	64
197	Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 5546-5552.	3.2	247
198	Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions. <i>Journal of Clinical Oncology</i> , 2011, 29, 254-256.	0.8	80

#	ARTICLE	IF	CITATIONS
199	The balance between benefits and harms of molecular targeted agents.. Journal of Clinical Oncology, 2011, 29, 6030-6030.	0.8	1
200	Absolute Benefits of Aromatase Inhibitors in Adjuvant Treatment of Breast Cancer: Should We Know More?. Journal of Clinical Oncology, 2010, 28, e346-e347.	0.8	5
201	Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells. Journal of the National Cancer Institute, 2010, 102, 1432-1446.	3.0	43
202	Do We Have to Change the Way Targeted Drugs Are Developed?. Journal of Clinical Oncology, 2010, 28, e420-e421.	0.8	12
203	Dose-dense treatment for triple-negative breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 79-80.	12.5	24
204	Zoledronic acid for breast cancer therapy-induced bone loss. Nature Reviews Clinical Oncology, 2010, 7, 187-188.	12.5	10
205	Personalized therapies in the cancer "omics" era. Molecular Cancer, 2010, 9, 202.	7.9	52
206	Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treatment Reviews, 2010, 36, 410-415.	3.4	27
207	Targeting DNA repair in breast cancer: A clinical and translational update. Cancer Treatment Reviews, 2010, 36, 557-565.	3.4	51
208	Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target. PLoS ONE, 2009, 4, e5565.	1.1	99
209	Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. Cancer Treatment Reviews, 2009, 35, 685-691.	3.4	52
210	Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer. Current Drug Targets, 2009, 10, 575-576.	1.0	18
211	Effect of dasatinib on the activity of trastuzumab in HER2-overexpressing breast cancer cells. Journal of Clinical Oncology, 2009, 27, 1084-1084.	0.8	3
212	An update on the biology of cancer stem cells in breast cancer. Clinical and Translational Oncology, 2008, 10, 786-793.	1.2	16
213	New options in the treatment of locally advanced head and neck cancer: Role for induction chemotherapy. Cancer Treatment Reviews, 2008, 34, 268-274.	3.4	17
214	Neuregulins and Cancer. Clinical Cancer Research, 2008, 14, 3237-3241.	3.2	95
215	Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options. Clinical Cancer Research, 2008, 14, 961-970.	3.2	42
216	Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Annals of Oncology, 2008, 19, 1860-1869.	0.6	57

#	ARTICLE	IF	CITATIONS
217	Third Nerve Palsy as the Initial Presenting Sign of Metastatic Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 407-408.	0.6	3
218	Hepatic Pneumatosis As a Complication of an Abdominal Desmoid Tumor. <i>Journal of Clinical Oncology</i> , 2007, 25, 897-898.	0.8	4
219	Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 628-638.	3.0	769
220	Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2656-2663.	0.8	53
221	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. <i>Annals of Oncology</i> , 2007, 18, 421-430.	0.6	40
222	Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients. <i>Cancer Letters</i> , 2007, 255, 71-76.	3.2	1
223	Tonic Clonic Seizure as the Presentation Symptom of Severe Hypocalcemia Secondary to Zoledronic Acid Administration. <i>Journal of Palliative Medicine</i> , 2007, 10, 1226-1227.	0.6	10
224	High TGF $\beta$ 2-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene. <i>Cancer Cell</i> , 2007, 11, 147-160.	7.7	446
225	An update into the pathophysiological role of HER2 in cancer: therapeutic implications. <i>Clinical and Translational Oncology</i> , 2007, 9, 543-544.	1.2	1
226	Insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 is active in breast cancer cells and enhances growth inhibition by herceptin through an increase in cell cycle arrest. <i>Journal of Clinical Oncology</i> , 2007, 25, 21077-21077.	0.8	2
227	Trastuzumab and Antiestrogen Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 90-95.	0.6	31
228	Concomitant Versus Sequential Chemotherapy in the Treatment of Early-Stage and Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 6, 495-504.	1.1	17
229	CASE 3. Upper Limb Lymphangiosarcoma Following Breast Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1477-1478.	0.8	9
230	Integrating trastuzumab in the treatment of breast cancer. Current status and future trends. <i>Clinical and Translational Oncology</i> , 2005, 7, 99-100.	1.2	8
231	Factors Predictive of Distant Metastases in Patients With Breast Cancer Who Have a Pathologic Complete Response After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 7098-7104.	0.8	98
232	Giant residual non-seminomatous mediastinal mass. <i>Oncologia</i> , 2004, 27, .	0.0	0
233	A new species and new combinations of <i>brevitobilus tsalolikhin</i> , 1981 (nematoda: tobrilidae) from Spain. <i>Journal of Nematology</i> , 1996, 28, 190-5.	0.4	1
234	Variability in the tail length of <i>Plectus aquatilis</i> Andrissy, 1985. <i>Nematologica</i> , 1991, 37, 116-119.	0.2	0

#	ARTICLE	IF	CITATIONS
235	A New Species of <i>Tobrilus</i> (Nematoda) From Spring Water. <i>Nematologica</i> , 1988, 34, 1-5.	0.2	4
236	Mapping Bromodomains in Breast Cancer and Its Association with Clinical Outcome. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1